Amyotrophic lateral sclerosis with IgM antibody against gangliosides GM2 and GD2

Internal Medicine

Volumn 42, Issue 3, 2003, Pages 277-280

  Mizutani, Kotaro ^e   Oka, Nobuyuki ^a   Kusunoki, Susumu ^b   Kaji, Ryuji ^c   Kanda, Masutaro ^d   Akiguchi, Ichiro ^e   Shibasaki, Hiroshi ^e  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TOKUSHIMA UNIVERSITY HOSPITAL   (Japan)

^d TAKEDA GENERAL HOSPITAL   (Japan)

^e KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti GM2 antibodies; Antiganglioside antibodies; Motor neuron disease

Indexed keywords

GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD2; GANGLIOSIDE GM2; IMMUNOGLOBULIN; IMMUNOGLOBULIN M;

ABSORPTION; ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ANTIBODY BLOOD LEVEL; ANTIBODY STRUCTURE; ANTIBODY TITER; ARM MUSCLE; ARTICLE; ASPHYXIA; CASE REPORT; CAUSE OF DEATH; CLINICAL FEATURE; DYSARTHRIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOPATHOLOGY; MOTOR NEURON DISEASE; MOTOR NEUROPATHY; MUSCLE WEAKNESS; NERVOUS SYSTEM ELECTROPHYSIOLOGY;

EID: 0242417041     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.42.277     Document Type: Article

References (34)

1. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59-62, 1993 (published erratum appears in Nature 364: 362, 1993).
2. Radunovic A, Leigh PN. Cu/Zn superoxide dismutase gene mutations in amyotrophic lateral sclerosis: correlation between genotype and clinical features. J Neurol Neurosurg Psychiatry 61: 565-572, 1996.
3. Engelhardt JI, Appel SH. IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis. Arch Neurol 47: 1210-1216, 1990.
4. Kawamata T, Akiyama H, Yamada T, McGeer PL. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol 140: 691-707, 1992.
5. Engelhardt JI, Tajti J, Appel SH. Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch Neurol 50: 30-36, 1993.
6. Shy ME, Rowland LP, Smith T, et al. Motor neuron disease and plasma cell dyscrasia. Neurology 36: 1429-1436, 1986.
7. Uchitel OD, Appel SH, Crawford F, Sczcupak L. Immunoglobulins from amyotrophic lateral sclerosis patients enhance spontaneous transmitter release from motor-nerve terminals. Proc Natl Acad Sci USA 85: 7371-7374, 1988.
8. Smith RG, Hamilton S, Hofmann F, et al. Serum antibodies to L-type calcium channels in patients with amyotrophic lateral sclerosis. N Engl J Med 327: 1721-1728, 1992.
9. Okuyama Y, Mizuno T, Inoue H, Kimoto K. Amyotrophic lateral sclerosis with anti-acetylcholine receptor antibody. Intern Med 36: 312-315, 1997.
10. Pestronk A, Cornblath DR, Ilyas AA, et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 24: 73-78, 1988.
11. Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible ruarker of Miller Fisher syndrome. Ann Neurol 31: 677-679, 1992.
12. Kusunoki S, Chiba A, Kon K, et al. N-Acetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain-Barré syndrome. Ann Neurol 35: 570-576, 1994.
13. Kaji R, Kusunoki S, Mizutani K, et al. Chronic motor axonal neuropathy associated with antibodies monospecific for N-acetylgalactosaminyl GD1a. Muscle Nerve 23: 702-706, 2000.
14. Weiss MD, Luciano CA, Semino-Mora C, Dalakas MC, Quarles RH. Molecular mimicry in chronic inflammatory demyelinating polyneuropathy and melanoma. Neurology 51: 1738-1741, 1998.
15. Vernant JC, Buisson G, Bellance R, Francois MA, Madkaud O, Zavaro O. Pseudo-amyotrophic lateral sclerosis, peripheral neuropathy and chronic polyradiculoneuritis in patients with HTLV-I-associated paraplegias. in: HTLV-I and the Nervous System. Roman GC, Vernant JC, Osame M, Eds. Alan R Liss, New York, 1989: 361-365.
16. Kaji R, Shibasaki H, Kimura J. Multifocal demyelinating motor neuropathy: cranial nerve involvement and immunoglobulin therapy. Neurology 42: 506-509, 1992.
17. van den Berg-Vos RM, Franssen H, Wokke JHJ, van Es HW, van den Berg LH. Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment. Ann Neurol 48: 919-926, 2000.
18. Cavanna B. Carpo M, Pedotti R, et al. Anti-GM2 IgM antibodies: clinical correlates and reactivity with a human neuroblastoma cell line. J Neuroimmunol 94: 157-164, 1999.
19. Irie S, Saito T, Nakamura K, et al. Association of anti-GM2 antibodies in Guillain-Barré syndrome with acute cytomegalovirus infection. J Neuroimmunol 68: 19-26, 1996.
20. Jacobs BC, van Doorn PA, Groeneveld JHM, Tio-Gillen AP, van der Meché FGA. Cytomegalovirus infections and anti-GM2 antibodies in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 62: 641-643, 1997.
21. Yuki N, Yamada M, Tagawa Y, Takahashi H, Handa S. Pathogenesis of the neurotoxicity caused by anti-GD2 antibody therapy. J Neurol Sci 149: 127-130, 1997.
22. Tai T, Cahan LD, Tsuchida T, Saxton RE, Irie RF, Morton DL. Immunogenicity of melanoma-associated gangliosides in cancer patients. Int J Cancer 35: 607-612, 1985.
23. Mizutani K, Oka N, Akiguchi I, et al. Enhancement of TNF-α production by ganglioside GM2 in human mononuclear cell culture. Neuroreport 10: 703-706, 1999.
24. Yoshino H, Michikawa M, Uchihara T, et al. Gangliosides and sulfated glucuronyl glycolipids in isolated bovine spinal motoneurons. Muscle Nerve Suppl 1: S158, 1994 (Abstract).
25. Matsumoto A, Yoshino H, Yuki N, et al. Ganglioside characterization of a cell line displaying motor neuron-like phenotype: GM2 as a possible major ganglioside in motor neurons. J Neurol Sci 131: 111-118, 1995.
26. Pestronk A, Adams RN, Clawson L, et al. Serum antibodies to GM1 ganglioside in amyotrophic lateral sclerosis. Neurology 38: 1457-1461, 1988.
27. Pestronk A, Adams RN, Cornblath D, Kuncl RW, Drachman DB, Clawson L. Patterns of serum IgM antibodies to GM1 and GD1a gangliosides in amyotrophic lateral sclerosis. Ann Neurol 25: 98-102, 1989.
28. Nobile-Orazio E, Legname G, Daverio R, et al. Motor neuron disease in a patient with a monoclonal IgMk directed against GM1, GD1b, and high-molecular-weight neural-specific glycoproteins. Ann Neurol 28: 190-194, 1990.
29. O'Hanlon GM, Veitch J, Gallardo E, Illa I, Chancellor AM, Willison HJ. Peripheral neuropathy associated with anti-GM2 ganglioside antibodies: clinical and immunopathological studies. Autoimmunity 32: 133-144, 2000.
30. Yuki N, Sato S, Miyatake T, Sugiyama K, Katagiri T, Sasaki H. Motoneuron-disease-like disorder after ganglioside therapy [letter]. Lancet 337: 1109-1110, 1991.
31. Yuki N, Miyatake T, Ichihashi Y, Sato S, Katagiri T. IgM anti-(GalNAc β1-4 Gal [3-2α NeuAc]β1-) antibody-mediated cytotoxicity in a patient with amyotrophic lateral sclerosis-like disorder [letter]. Muscle Nerve 15: 1371-1373, 1992.
32. Nakao T, Kon K, Ando S, et al. Novel lacto-ganglio type gangliosides with GM2-epitope in bovine brain which react with IgM from a patient of the amyotrophic lateral sclerosis-like disorder. J Biol Chem 268: 21028-21034, 1993.
33. Drachman DB, Kuncl RW. Amyotrophic lateral sclerosis: an unconventional autoimmune disease? Ann Neurol 26: 269-274, 1989.
34. Ortiz N, Rosa R, Gallardo E, et al. IgM monoclonal antibody against terminal moiety of GM2, GalNAc-GD1a and GalNAc-GM1b from a pure motor chronic demyelinating polyneuropathy patient: effects on neurotransmitter release. J Neuroimmunol 119: 114-123, f2001.